Yongduo Yu

Yongduo Yu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
TZTao Zhang
Tao Zhang
MCMeng Chen
Meng Chen
ZYZhitong Yu
Zhitong Yu
ZRZhetan Ren
Zhetan Ren
LWLing Wang
Ling Wang
YYYongduo Yu
Yongduo Yu
This study aimed to evaluate the burden and trends of paralytic ileus and bowel obstruction in individuals aged ≥ 65 years, offering insights into prevention, treatment, and healthcare policy. Data from the Global Burden of Disease Study 2021 were used to analyze paralytic ileus and intestinal obstruction by demographics, year, country/region, and Socio-Demographic Index (SDI). The statistical methods included Joinpoint regression, decomposition analysis, and Bayesian Age-Period-Cohort modeling. In 2021, the global age-standardized incidence of paralytic ileus and intestinal obstruction among the elderly was 643.45 cases per 100,000 individuals. The corresponding prevalence was 24.05 per 100,000 individuals, with disability-adjusted life years (DALYs) of 294.01 per 100,000 person-years and a mortality rate of 20.55 per 100,000 individuals. Between 1990 and 2021, the age-standardized incidence and prevalence of paralytic ileus and intestinal obstruction in the elderly gradually increased, while age-standardized DALYs and mortality consistently declined. Despite similar trends observed across both genders, the disease burden increased with age and was more pronounced in males than in females. Furthermore, the age-standardized incidence and prevalence of these conditions increased with SDI, whereas mortality and DALYs decreased. By 2030, the incidence and prevalence are expected to continue increasing, whereas mortality and DALYs are expected to decrease. Despite the consistent decrease in mortality and DALYs associated with paralytic ileus and bowel obstruction in the elderly population aged ≥ 65 years, their incidence and prevalence continue to increase annually. This underscores the importance of improving preventive measures, early screening, and treatment efforts to address this pressing public health challenge.

8 February 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YYYan Yu
Yan Yu
ZWZhenqi Wu
Zhenqi Wu
YHYu Han
Yu Han
YYYuan Yuan
Yuan Yuan
HFHui Fan
Hui Fan
YYYongduo Yu
Yongduo Yu
Background. Atractylodes lancea (AL) has been used in traditional Chinese medicine for the treatment of various diseases including digestive disorders. Ulcerative colitis (UC) is a common digestive system disease with a low cure rate and easy recurrence. However, it is still not clear whether AL is suitable for UC treatment. Currently, stir-baking with wheat bran is most commonly used to process AL. Here, we aimed to address the effects of the crude and bran-processed AL on UC in vitro and uncover the underlying mechanism based on regulating the IKK/NF-kappa B signaling pathway. Methods. Human colonic epithelial cells (HCoEpiC) were treated with lipopolysaccharide (LPS) to mimic the inflammatory injury of UC in vitro. The essential oil from crude and bran-processed AL was used to treat LPS-induced HcoEpiC cells. The cell viability was detected by an MTT assay. The levels of IL-4, IL-6, IL-8, IL-12, IL-1-β, TNF-α, and NO were determined by ELISA, and the mRNA expressions of IKK-α, NF-κB, IL-4, IL-6, IL-8, and TNF-α were determined by RT-PCR. Meanwhile, the expressions of IKK-α, p-IKK-α, p-IKK-β, NF-κB, IL-6, and IL-8 proteins were determined by Western blot. Results. The essential oil of AL, whether it was from crude or bran-processed AL, could significantly increase the viability of LPS-induced HCoEpiC cells. The treatment of AL essential oil also notably inhibited the productions of IL-6, IL-8, IL-12, IL-1-β, TNF-α, NO, p-IKK-α, p-IKK-β, and NF-κB and downregulated the mRNA expressions of NF-κB, IL-6, IL-8, and TNF-α. Meanwhile, IL-4 protein and mRNA expression were significantly stimulated by AL essential oil. Moreover, the essential oil from bran-processed AL was more effective than that from crude AL. Conclusion. Both kinds of AL essential oil had the anti-inflammatory effect on LPS-induced HCoEpiC, and the essential oil from bran-processed AL was more effective. The mechanism could be through the IKK/NF-κB signaling pathway in vitro.

21 April 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
ZPZhengchao Pan
Zhengchao Pan
TZTao Zhang
Tao Zhang
ZRZhetan Ren
Zhetan Ren
HZHongkun Zhang
Hongkun Zhang
JWJing Wang
Jing Wang
YYYongduo Yu
Yongduo Yu
Constipation is a common functional gastrointestinal disorder with a complex pathogenesis. Traditional studies have primarily explained its development in terms of reduced intestinal motility or impaired defecatory coordination; however, these mechanisms alone cannot fully account for the multifactorial pathological processes underlying the condition. In recent years, increasing attention has been directed toward the roles of intestinal microbial dysbiosis and alterations in immune homeostasis in the development of constipation. The gut microbiota continuously interacts with the intestinal immune system through its structural components, metabolic products, and secreted molecules. These interactions modulate the mucosal immune microenvironment and participate in the regulation of intestinal motility by influencing the enteric nervous system, interstitial cells of Cajal, and smooth muscle function. Conversely, the immune system can reshape the composition and spatial distribution of the gut microbiota through mechanisms such as the mucosal barrier, immunoglobulin A, and antimicrobial peptides, thereby forming a bidirectional regulatory network. Accumulating evidence suggests that during the onset and progression of constipation, microbial dysbiosis, shifts in immune homeostasis, and abnormalities in intestinal motility may evolve through a progressively amplifying dynamic process, ultimately establishing a self-sustaining chronic cycle. In addition, microbiota-targeted interventions—including probiotics, prebiotics, and fecal microbiota transplantation—have demonstrated potential benefits in improving stool frequency and stool consistency in several clinical studies. However, the immunological mechanisms underlying these effects remain relatively underexplored. This review systematically summarizes the molecular mechanisms by which gut microbiota–immune interactions regulate intestinal motility. By integrating current evidence on disease progression and clinical studies, we propose a conceptual model of the “microbiota–immune–motility regulatory axis,” aiming to provide a new perspective for understanding the pathogenesis of constipation and for optimizing microbiota-based therapeutic strategies.

2 January 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
TZTao Zhang
Tao Zhang
ZRZhetan Ren
Zhetan Ren
BTBowen Tang
Bowen Tang
RMRu Man
Ru Man
LWLin Wang
Lin Wang
YYYongduo Yu
Yongduo Yu
Gastrointestinal tumors (GITs), particularly gastric and colorectal cancers, are the leading causes of cancer-related deaths worldwide. Despite advances in screening technologies and the continuous development of treatments, which have improved early diagnosis and therapeutic interventions, the morbidity and mortality rates remain high, presenting a significant challenge to global public health. While existing treatments can extend patient survival to some degree, they are often accompanied by substantial side effects. In recent years, immunotherapy has yielded positive outcomes for some patients. However, the emergence of immune escape mechanisms has hindered treatment effectiveness. As a result, there is an urgent need for new therapeutic strategies that can address the limitations of current approaches. mitophagy, a key cellular process, has gained significant attention in cancer research. It plays an essential role in maintaining cellular energy balance and metabolic stability, and is intricately linked to crucial biological processes such as drug resistance, metastasis, invasion, and the tumor microenvironment. This article aims to provide a comprehensive review of the mechanisms underlying mitophagy, examining its role in gastrointestinal cancers, particularly in relation to cellular metabolism, apoptosis, drug resistance, metastasis, invasion, and the tumor microenvironment. Additionally, it will explore the potential of mitophagy as a therapeutic target and address current clinical challenges. It is hoped that this research will offer new insights and directions for the treatment of GITs.

1 October 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
YQYingchao Qi
Yingchao Qi
YWYichen Wang
Yichen Wang
SZSiyao Zhang
Siyao Zhang
XPXinxin Pan
Xinxin Pan
WLWenkai Li
Wenkai Li
YYYongduo Yu
Yongduo Yu
Background: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by a dysregulated mucosal immune response in the intestine. The disease poses significant challenges for both diagnosis and treatment. This study aims to identify reliable biomarkers for UC and investigate its immunological characteristics, with the goal of improving diagnostic accuracy and informing treatment strategies. Methods: This study integrated multiple GEO datasets and identified UC-associated hub genes through differential expression and Weighted Gene Co-expression Network Analysis (WGCNA), with subsequent refinement using least absolute shrinkage and selection operator (LASSO), randomForest (RF), and support vector machine-recursive feature elimination (SVM-RFE) algorithms. These genes were used to construct a feedforward neural network (FNN) diagnostic model, whose performance was assessed using receiver operating characteristic (ROC) curve analysis. Immune profiling based on CIBERSORT, ssGSEA, Gene set variation analysis (GSVA), and ESTIMATE revealed associations between hub gene expression, immune cell infiltration, and inflammatory activity. Immunohistochemistry was performed to validate the protein expression of hub genes. Results: Ten hub genes (ACOX2, MMP3, CPT2, CTSK, CHP2, VCAM1, SLC25A34, BASP1, NCF2, and GLB1L2) were identified, and the FNN model showed strong diagnostic accuracy. Notably, NCF2 expression correlated with immune cell infiltration and immune/inflammation scores, and was confirmed to be elevated in UC tissues, suggesting a key role in disease pathogenesis. Conclusion: This study identified ten hub genes with potential as biomarkers for the diagnosis and treatment of UC. NCF2 may contribute to UC pathogenesis by modulating inflammatory and immune responses, serving as a potential immune-related biomarker for improved UC diagnosis and treatment.

2 June 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
TZTao Zhang
Tao Zhang
LWLin Wang
Lin Wang
ZRZhetan Ren
Zhetan Ren
RMRu Man
Ru Man
XCXiaozhen Cheng
Xiaozhen Cheng
YYYongduo Yu
Yongduo Yu
Background: Anxiety and depression are highly prevalent among patients with inflammatory bowel disease (IBD) and are closely associated with reduced quality of life and poor treatment adherence. The gut–brain axis has been proposed as a key mechanistic framework, with the gut microbiota playing a central role. However, findings from clinical studies remain inconsistent, and a comprehensive synthesis of the evidence is lacking. Objective: This systematic review aimed to integrate evidence from randomized controlled trials (RCTs) and prospective cohort studies to evaluate the associations between gut microbiota characteristics, microbiota-targeted interventions, and symptoms of anxiety and depression in patients with IBD. Methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, EBSCOhost, and Scopus. The search covered records from database inception to October 17, 2025. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A descriptive synthesis approach was used to summarize the findings. Study quality was assessed using the Critical Appraisal Skills Programme (CASP) checklist. Results: Ten studies were included, comprising six prospective cohort studies and four RCTs. These studies included a total of 1,040 patients with IBD. Cohort studies consistently showed that anxiety and depressive symptoms were associated with reduced microbial α-diversity, enrichment of pro-inflammatory taxa, and depletion of short-chain fatty acid (SCFA)-producing bacteria. These associations persisted after adjustment for inflammatory markers. They were also observed when analyses were restricted to patients in remission. This suggests that the associations may not be fully explained by disease activity. Evidence from RCTs showed that microbiota-targeted interventions, including probiotics and fecal microbiota transplantation, modulated microbial composition and reduced anxiety and depression scores. Studies combining psychological interventions with microbiota profiling also suggested potential effects on gut microbial composition. However, the findings remain heterogeneous. Conclusion: Current evidence supports a close and potentially bidirectional association between gut microbiota dysbiosis and anxiety and depression in patients with IBD. Both microbiota-targeted interventions and psychological therapies may represent promising strategies for managing psychological comorbidities in IBD. Future large-scale, standardized longitudinal studies and randomized controlled trials are warranted to clarify directionality, test causal hypotheses, and develop personalized intervention approaches. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251166542.